|
HUE066566T2
(hu)
|
2017-07-24 |
2024-08-28 |
Novartis Ag |
Vegyületek és készítmények NLRP aktivitással összefüggõ állapotok kezelésére
|
|
TW201910316A
(zh)
|
2017-08-15 |
2019-03-16 |
愛爾蘭商英弗雷佐姆有限公司 |
新穎化合物
|
|
US11623922B2
(en)
|
2017-10-03 |
2023-04-11 |
Inflazome Limited |
Compounds
|
|
JP2021529186A
(ja)
*
|
2018-07-03 |
2021-10-28 |
ノバルティス アーゲー |
Ｎｌｒｐ調節剤
|
|
CA3103664A1
(en)
*
|
2018-07-03 |
2020-01-09 |
Novartis Ag |
Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
CN112672995A
(zh)
|
2018-08-15 |
2021-04-16 |
英夫拉索姆有限公司 |
新型磺酰胺脲化合物
|
|
PL3880660T3
(pl)
*
|
2018-11-13 |
2025-11-12 |
Novartis Ag |
Związki i kompozycje do leczenia stanów związanych z aktywnością nlrp
|
|
ES2957692T3
(es)
|
2018-11-13 |
2024-01-24 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
|
|
WO2020102574A1
(en)
*
|
2018-11-16 |
2020-05-22 |
Novartis Inflammasome Research, Inc. |
The compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201819083D0
(en)
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
EP3986879B1
(en)
|
2019-06-21 |
2024-10-02 |
AC Immune SA |
Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators
|
|
WO2021002887A1
(en)
*
|
2019-07-02 |
2021-01-07 |
Novartis Inflammasome Research, Inc. |
Gut-targeted nlrp3 antagonists and their use in therapy
|
|
EP4013761A1
(en)
|
2019-08-16 |
2022-06-22 |
Inflazome Limited |
Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors
|
|
TW202115095A
(zh)
|
2019-08-16 |
2021-04-16 |
愛爾蘭商英弗雷佐姆有限公司 |
新穎化合物
|
|
JP2022547882A
(ja)
|
2019-09-06 |
2022-11-16 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤
|
|
US20230121952A1
(en)
|
2020-02-18 |
2023-04-20 |
Inflazome Limited |
Compounds
|
|
EP4132505A4
(en)
|
2020-03-25 |
2024-04-24 |
Olatec Therapeutics, Inc. |
Method for treating diabetes
|
|
IL299084A
(en)
|
2020-06-19 |
2023-02-01 |
Ac Immune Sa |
History of dihydrooxazole and thiourea or urea modulating the NLRP3 inflammasome pathway
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
CN116917282A
(zh)
*
|
2021-05-10 |
2023-10-20 |
成都百裕制药股份有限公司 |
酰胺衍生物及其应用
|
|
US20250109126A1
(en)
|
2021-12-22 |
2025-04-03 |
Ac Immune Sa |
Dihydro-oxazol derivative compounds
|
|
EP4554945A1
(en)
|
2022-07-14 |
2025-05-21 |
AC Immune SA |
Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
|
|
CA3261365A1
(en)
|
2022-07-28 |
2024-02-01 |
Ac Immune Sa |
NEW COMPOUNDS
|
|
EP4719599A1
(en)
|
2023-06-02 |
2026-04-08 |
Merck Sharp & Dohme LLC |
5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
WO2025153532A1
(en)
|
2024-01-16 |
2025-07-24 |
NodThera Limited |
Nlrp3 inhibitors and glp-1 agonists combination therapies
|
|
WO2025153624A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025153625A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|
|
WO2026057747A1
(en)
|
2024-09-11 |
2026-03-19 |
Ac Immune Sa |
Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
|
|
CN119680348A
(zh)
*
|
2025-02-05 |
2025-03-25 |
上海惠志环保科技有限公司 |
一种应用于含高浓度二氯甲烷废气处理方法及其系统
|